Harnessing the power of evolution to develop life-changing medicines

Evolution is our platform.
Patients are our purpose.

Evolution has already honed molecules and mechanisms that overcome life-threatening conditions. This occurred over hundreds of millions of years of evolutionary time.

Elephants are resistant to cancer because their genomes contain dozens of copies of a tumor-suppressive gene (for reference, humans only have two copies).

An ancient Chinese tree holds innate, anti-cancer fighting properties that have been shown to effectively treat cancer.

Newborns decrease their inflammatory immune response during the first 48 hours of life, allowing for their microbiomes to colonize without overwhelming inflammation.

At Peel, we translate these awe-inspiring discoveries into medicines for patients with life-threatening diseases. By applying our expertise in evolutionary and molecular biology with a deep understanding of how medicines function in the human body, we dynamically engineer these natural molecules into safe and efficacious treatments for people with devastating cancers and inflammatory diseases.

The Peel R&D engine: Picking up where nature left off

At Peel Therapeutics, our technologies and expertise enable us to determine and deliver on the therapeutic potential of evolutionary outliers that circumvent disease.

Our team seeks the distinct molecules in nature based on the latest academic literature and evolutionary discoveries that exceed what we’ve deemed biologically possible. We are selective in the programs we evaluate and our process includes assessing assets’ molecule’s structure our and its impact on physiology, patients efficacy and safety.

Our multidisciplinary R&D team including biochemistry, molecular biology, evolutionary biology, immunology, cancer research, protein and chemical engineering, drug delivery, clinical trials and medical practice creates a deep understanding of these molecules coupled with our experience in drug delivery enables us to develop these medicines to have a lasting impact for patients.

PEEL ISRAEL AND EARLY DISCOVERY

One of our biggest advantages is our Peel Israel site focused on early discovery and lead candidate development. The scientists of Peel Israel have vast experience in molecular biology, protein engineering, analytical biochemistry, immunology, and drug delivery. The labs are equipped with state-of-the-art instruments and additional high-end equipment is available at the adjacent Technion Israel-Institute of Technology Cores. Peel Israel’s nimble drug development processes redesign nature’s offerings into medicines by improving formulation, stability, and efficacy. Our Peel Israel site acts as the springboard for Peel’s drug pipeline and IND-enabling studies.

Step 1
Evolution of Solutions

Over millions of years, nature evolves mechanisms to treat and prevent disease.
Step 2
Concept Discovery

Peel works with academic scientists discover mechanisms in nature and demonstrate proof-of-concept in relevant disease models.
Step 3
Asset Selection

Peel selects assets to license from academic institutions based on: alignment of our mission, potential impact on patient lives and likelihood of project success.
Step 4
Optimization of Nature

Peel’s R&D team engineers and formulates assets to maximize solubility, scalability, and bioavailability.
Step 5
Development for Clinic

Peel’s team works with CDMOs and CROs to produce all material and data required for regulatory approval to test the drug in human clinical trials.
Step 6
Translation to Patients

Peel’s clinical team works with CROs to bring our assets directly to patients in clinical trials to test safety and efficacy.

We are currently enrolling a Phase 1 Clinical Trial for chemotherapy resistant solid tumors

Visit Clinicaltrials.gov

Publications and Presentations

Recent PEEL-224 EP53 NTP

Elephant TP53-RETROGENE 9 induces transcription-independent apoptosis at the mitochondria

February 16, 2023

https://pubmed.ncbi.nlm.nih.gov/36797268/

Neonatal NET-Inhibitory Factor improves survival in the cecal ligation and puncture model of polymicrobial by inhibiting neutrophil extracellular traps

January 17, 2023

https://pubmed.ncbi.nlm.nih.gov/36733389/

Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors

October 1, 2020

https://pubmed.ncbi.nlm.nih.gov/32839252/

Accelerated Evolution in Distinctive Species Reveals Candidate Elements for Clinically Relevant Traits, Including Mutation and Cancer Resistance

March 6, 2018

https://pubmed.ncbi.nlm.nih.gov/29514101/

Potential Mechanisms for Cancer Resistance in Elephants and Comparative Cellular Response to DNA Damage in Humans

November 3, 2015

https://pubmed.ncbi.nlm.nih.gov/26447779/

Neonatal NET-Inhibitory Factor improves survival in the cecal ligation and puncture model of polymicrobial by inhibiting neutrophil extracellular traps

January 17, 2023

https://pubmed.ncbi.nlm.nih.gov/36733389/

Harnessing the power of evolution to develop life-changing medicines

Evolution is our platform.
Patients are our purpose.

The Peel R&D engine: Picking up where nature left off

PEEL ISRAEL AND EARLY DISCOVERY

Evolution of Solutions

Concept Discovery

Asset Selection

Optimization of Nature

Development for Clinic

Translation to Patients

We are currently enrolling a Phase 1 Clinical Trial for chemotherapy resistant solid tumors

Publications and Presentations

Elephant TP53-RETROGENE 9 induces transcription-independent apoptosis at the mitochondria

Neonatal NET-Inhibitory Factor improves survival in the cecal ligation and puncture model of polymicrobial by inhibiting neutrophil extracellular traps

Of Elephants and Other Mammals: A Comparative Review of Reproductive Tumors and Potential Impact on Conservation

Neutrophil extracellular trap inhibition improves survival in neonatal mouse infectious peritonitis

Neutrophil Extracellular Traps Regulate Ischemic Stroke Brain Injury

Elephant Genomes Reveal Accelerated Evolution in Mechanisms Underlying Disease Defenses

Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome

Cancer therapeutics inspired by defense mechanisms in the animal kingdom

Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors

Elephant TP53-RETROGENE 9 induces transcription-independent apoptosis at the mitochondria

Of Elephants and Other Mammals: A Comparative Review of Reproductive Tumors and Potential Impact on Conservation

Elephant Genomes Reveal Accelerated Evolution in Mechanisms Underlying Disease Defenses

Cancer therapeutics inspired by defense mechanisms in the animal kingdom

Accelerated Evolution in Distinctive Species Reveals Candidate Elements for Clinically Relevant Traits, Including Mutation and Cancer Resistance

Potential Mechanisms for Cancer Resistance in Elephants and Comparative Cellular Response to DNA Damage in Humans

Neonatal NET-Inhibitory Factor improves survival in the cecal ligation and puncture model of polymicrobial by inhibiting neutrophil extracellular traps

Neutrophil extracellular trap inhibition improves survival in neonatal mouse infectious peritonitis

Neutrophil Extracellular Traps Regulate Ischemic Stroke Brain Injury

Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome

Neonatal NET-inhibitory factor and related peptides inhibit neutrophil extracellular trap formation

Harnessing the power of evolution to develop life-changing medicines

Evolution is our platform.Patients are our purpose.

The Peel R&D engine: Picking up where nature left off

PEEL ISRAEL AND EARLY DISCOVERY

Evolution of Solutions

Concept Discovery

Asset Selection

Optimization of Nature

Development for Clinic

Translation to Patients

We are currently enrolling a Phase 1 Clinical Trial for chemotherapy resistant solid tumors

Publications and Presentations

Evolution is our platform.
Patients are our purpose.